Floatz logo

Axitinib

Kidney Cancer

Stephanie BergSmall moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
73/ 100

Competitive context

68 Active assets in the Kidney Cancer cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
Dartmouth-Hitchcock Medical Center
Phase 3BBB
Girentuximab
Memorial Sloan Kettering Cancer Center
Phase 3BB
Etoposide
City of Hope Medical Center
Phase 3BB
Nivestim
National Institutes of Health Clinical Center (CC)
Phase 3BB
Fluorouracilum
Medical Research Council
Phase 3BB

View all 50 →

Same molecule, other indications

Axitinib is also rated in:

kidney neoplasmActive
BB
Indicative · Phase 3
69 / 100
View asset →
renal cell carcinomaActive
BB
Indicative · Phase 4
67 / 100
View asset →
clear cell renal carcinomaDormant
B
Indicative · Phase 3
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →